Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
Mesoblast Limited announced that its FDA-approved cell therapy Ryoncil® generated net sales of US$30.3 million in Q1 2026, with strong growth in February and March offsetting January seasonality. Total revenue from Ryoncil® since launch approaches US$100 million, strengthening Mesoblast's balance sheet and supporting ongoing label extension and lat…